selenious acid · Am Regent · NDA 209379
Selenious Acid
Earliest generic entry, as listed · earliest of 3 marketed strengths
1 Jul 2041
Blocked by patent: US 11998565, US 12150957.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11998565 | product | 1 Jul 2041 |
| US 12150957 | use U-4039 | 1 Jul 2041 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- 25 Oct 2026Generic approved · 209379-00131 Dec 2025
- 25 Oct 2026Generic approved · 209379-0013 Feb 2026
- 25 Oct 2026Generic approved · 209379-00130 Jun 2026
Products covered · 3
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 209379 · 001 · RLD | solution, intravenous | EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML) | 1 Jul 2041 |
| 209379 · 002 · RLD | solution, intravenous | EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML) | 1 Jul 2041 |
| 209379 · 003 · RLD | solution, intravenous | EQ 12MCG SELENIUM/2ML (EQ 6MCG SELENIUM/ML) | 1 Jul 2041 |